
Levoxyl is owned by Pfizer Inc. (NYSE: PFE), which acquired the brand with its $3.6 billion purchase of King Pharmaceuticals in 2011. Originally developed by Jones Pharma and FDA approved in May 2001, Levoxyl is a levothyroxine sodium tablet used to treat hypothyroidism and for pituitary TSH suppression.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Levoxyl | Pfizer Inc. | Product line |
Levothyroxine products were marketed in the United States for decades without formal FDA approval under pre-1962 rules. That changed in August 1997, when the FDA declared that all orally administered levothyroxine sodium products were new drugs and that manufacturers needed approved applications to keep selling them.
Jones Pharma, the St. Louis specialty company, had been marketing its levothyroxine product as Levoxyl. When King Pharmaceuticals absorbed Jones in August 2000, the application work continued under King. On May 25, 2001, the FDA approved King's NDA for Levoxyl, making it one of the first levothyroxine products to gain formal approval, alongside Jerome Stevens' Unithroid.
Through the 2000s, Levoxyl competed in a branded levothyroxine market led by Synthroid, with Levoxyl positioned as a mid-priced alternative. King's specialty business model relied on brands like Levoxyl, Altace, and Skelaxin to generate steady cash flow.
Pfizer bought King in a deal announced in October 2010 and closed in February 2011. The acquisition, valued at roughly $3.6 billion, was primarily about King's pain management and abuse-deterrent portfolio, but Levoxyl came along as a durable specialty product.
The brand's most difficult period followed. In 2013, Pfizer recalled Levoxyl twice: first over musty odors traced to oxygen-absorbing canisters in bottles, then over potency failures in stability testing affecting 84 lots. The recalls created a shortage that placed Levoxyl on the FDA's drug shortage list and kept the product largely unavailable until 2014. Pfizer reformulated and resumed supply, but the episode cost the brand share it has not fully regained.
Since then, Levoxyl has persisted as a steady, small branded product inside Pfizer's portfolio: still prescribed, still listed by pharmacies alongside Synthroid, Unithroid, and Tirosint, and still an option for patients stabilized on it.
What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.
Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.
Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.
Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.
How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.
Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.
What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.
The 2013 double recall is the brand's principal controversy. In early 2013, Pfizer's King subsidiary began recalling Levoxyl after consumer complaints of musty odors, traced to oxygen-absorbing canisters in 100-count and 1,000-count bottles. While addressing that issue with a reformulation, the company found that batches of the older formulation were failing potency specifications in stability testing, and it recalled 84 lots at the retail level.
The combined recalls produced a genuine shortage. Pfizer told the medical community it did not expect resupply until 2014, and Levoxyl appeared on the FDA drug shortage list. Patients had to transition to other levothyroxine products under medical supervision, a sensitive process given the drug's narrow therapeutic index.
Beyond the recalls, Levoxyl's regulatory history is routine for a mature branded pharmaceutical: standard FDA inspections, labeling updates, and the usual monitoring of a narrow therapeutic index product.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Abbvie | USA | 1955 | Mass market | United states | All Genders | |
| Amneal Pharmaceuticals | USA | 2000 | Mass market | United states | All Genders | |
| Abbvie | USA | 1900 | Mass market | United states | All Genders | |
| Ibsa | Switzerland | 2006 | Premium | United states | All Genders | |
| Ibsa | Switzerland | 2016 | Mass market | United states | All Genders |
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's levothyroxine brand for hypothyroidism, first marketed in 1955 and long among the most prescribed medications in the United States.
Healthcare PharmaceuticalsOwned by Amneal Pharmaceuticals, Inc.
Levothyroxine tablet for hypothyroidism, the first FDA-approved levothyroxine product, manufactured by Jerome Stevens Pharmaceuticals and distributed by Amneal.
Healthcare PharmaceuticalsOwned by AbbVie Inc.
AbbVie's natural desiccated thyroid brand derived from porcine thyroid glands, used for hypothyroidism for more than a century and acquired through Forest, Actavis, and Allergan.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Pharma's liquid levothyroxine oral solution, the first and only FDA-approved liquid levothyroxine, marketed in monodose ampules for hypothyroidism since 2019 in the US.
Market Positioning: Levoxyl competes with 5 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Pfizer Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Levoxyl which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Pharma's liquid levothyroxine oral solution, the first and only FDA-approved liquid levothyroxine, marketed in monodose ampules for hypothyroidism since 2019 in the US.
Tirosint-SOL is privately owned, unlike Levoxyl which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Levoxyl which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Levoxyl which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Global Medical Response
America's largest air ambulance membership network, covering more than 3 million members across 38 states, operated by Global Medical Response.
AirMedCare Network is privately owned, unlike Levoxyl which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike Levoxyl which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.